04:00 PM EDT, 05/01/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lift our target price to $150 from $128, 14.9x our 2025 EPS forecast, a discount to ALGN's historical forward average due to soft demand in the dental market. Our upgrade reflects our view that demand is starting to show signs of improvement, particularly for younger patients. We maintain our 2025 EPS estimate of $10.07 and trim 2026 by $0.04 to $11.12. Q1 EPS of $2.13 vs. $2.14 exceeded consensus by $0.14. In our view, Q1 2025 results were mixed, with revenue and earnings declining Y/Y, but Clear Aligner volumes growing. Sales fell 1.8% Y/Y, due to unfavorable FX and a shift in product mix toward lower-priced offerings. However, Clear Aligner volumes grew 6.2% Y/Y, but Clear Aligner sales declined 2.5% Y/Y to due to lower average selling prices. Operating margin fell 70 bps Y/Y to 19.1%, also due to unfavorable FX, partially offset by lower manufacturing spend. We see less tariff exposure than anticipated, with most of the exposure limited to iTero scanners, which are manufactured in Israel.